Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy
© 2023. The Author(s)..
BACKGROUND: Oncolytic virotherapy (OVT) is a promising anti-tumor modality that utilizes oncolytic viruses (OVs) to preferentially attack cancers rather than normal tissues. With the understanding particularly in the characteristics of viruses and tumor cells, numerous innovative OVs have been engineered to conquer cancers, such as Talimogene Laherparepvec (T-VEC) and tasadenoturev (DNX-2401). However, the therapeutic safety and efficacy must be further optimized and balanced to ensure the superior safe and efficient OVT in clinics, and reasonable combination therapy strategies are also important challenges worthy to be explored.
MAIN BODY: Here we provided a critical review of the development history and status of OVT, emphasizing the mechanisms of enhancing both safety and efficacy. We propose that oncolytic virotherapy has evolved into the fourth generation as tumor immunotherapy. Particularly, to arouse T cells by designing OVs expressing bi-specific T cell activator (BiTA) is a promising strategy of killing two birds with one stone. Amazing combination of therapeutic strategies of OVs and immune cells confers immense potential for managing cancers. Moreover, the attractive preclinical OVT addressed recently, and the OVT in clinical trials were systematically reviewed.
CONCLUSION: OVs, which are advancing into clinical trials, are being envisioned as the frontier clinical anti-tumor agents coming soon.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Journal of translational medicine - 21(2023), 1 vom: 25. Juli, Seite 500 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Xianwang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
BiTA |
|---|
| Anmerkungen: |
Date Completed 27.07.2023 Date Revised 28.07.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12967-023-04360-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359914330 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359914330 | ||
| 003 | DE-627 | ||
| 005 | 20231226081906.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12967-023-04360-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1199.xml |
| 035 | |a (DE-627)NLM359914330 | ||
| 035 | |a (NLM)37491263 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Xianwang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.07.2023 | ||
| 500 | |a Date Revised 28.07.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a BACKGROUND: Oncolytic virotherapy (OVT) is a promising anti-tumor modality that utilizes oncolytic viruses (OVs) to preferentially attack cancers rather than normal tissues. With the understanding particularly in the characteristics of viruses and tumor cells, numerous innovative OVs have been engineered to conquer cancers, such as Talimogene Laherparepvec (T-VEC) and tasadenoturev (DNX-2401). However, the therapeutic safety and efficacy must be further optimized and balanced to ensure the superior safe and efficient OVT in clinics, and reasonable combination therapy strategies are also important challenges worthy to be explored | ||
| 520 | |a MAIN BODY: Here we provided a critical review of the development history and status of OVT, emphasizing the mechanisms of enhancing both safety and efficacy. We propose that oncolytic virotherapy has evolved into the fourth generation as tumor immunotherapy. Particularly, to arouse T cells by designing OVs expressing bi-specific T cell activator (BiTA) is a promising strategy of killing two birds with one stone. Amazing combination of therapeutic strategies of OVs and immune cells confers immense potential for managing cancers. Moreover, the attractive preclinical OVT addressed recently, and the OVT in clinical trials were systematically reviewed | ||
| 520 | |a CONCLUSION: OVs, which are advancing into clinical trials, are being envisioned as the frontier clinical anti-tumor agents coming soon | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a BiTA | |
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a Oncolytic virotherapy (OVT) | |
| 650 | 4 | |a Oncolytic viruses (OVs) | |
| 650 | 4 | |a T-VEC | |
| 700 | 1 | |a Shen, Yihua |e verfasserin |4 aut | |
| 700 | 1 | |a Wan, Xingxia |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Xiaoqing |e verfasserin |4 aut | |
| 700 | 1 | |a Cai, Wen-Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Zijun |e verfasserin |4 aut | |
| 700 | 1 | |a Xin, Qiang |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Xiaoqing |e verfasserin |4 aut | |
| 700 | 1 | |a Gui, Jingang |e verfasserin |4 aut | |
| 700 | 1 | |a Xin, Hong-Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Xin, Hong-Wu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of translational medicine |d 2003 |g 21(2023), 1 vom: 25. Juli, Seite 500 |w (DE-627)NLM142679194 |x 1479-5876 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2023 |g number:1 |g day:25 |g month:07 |g pages:500 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12967-023-04360-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2023 |e 1 |b 25 |c 07 |h 500 | ||